Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 175

Results For "innovative"

1780 News Found

Lonza extends collaboration with Biopharma company
News | July 19, 2021

Lonza extends collaboration with Biopharma company

As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies


Zydus Cadila receives USFDA approval for Emtricitabine and Tenofovir Disoproxil
News | July 04, 2021

Zydus Cadila receives USFDA approval for Emtricitabine and Tenofovir Disoproxil

The drug is used with other HIV medications to help control HIV infection and it helps to decrease the amount of HIV in one’s body so that the immune system can work better


Triastek closes US $50 Mn Series B Financing
News | July 01, 2021

Triastek closes US $50 Mn Series B Financing

In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline


Lonza to expand API manufacturing facility in Nansha, China
News | June 28, 2021

Lonza to expand API manufacturing facility in Nansha, China

The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022


Zydus Cadila receives tentative approval from USFDA for Pemetrexed
News | June 26, 2021

Zydus Cadila receives tentative approval from USFDA for Pemetrexed

Pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells


Zydus Cadila receives USFDA approval for Fingolimod capsules
News | June 25, 2021

Zydus Cadila receives USFDA approval for Fingolimod capsules

Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis


Poxel and Sumitomo Dainippon gets TWYMEEG approval
News | June 25, 2021

Poxel and Sumitomo Dainippon gets TWYMEEG approval

The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies


Zydus and Bayer announce extension of their JV
News | June 21, 2021

Zydus and Bayer announce extension of their JV

Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline


Zydus Cadila receives tentative USFDA approval for Brivaracetam
News | June 15, 2021

Zydus Cadila receives tentative USFDA approval for Brivaracetam

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad


Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
News | June 14, 2021

Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years

The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination